SCHEMBL733193

SCHEMBL733193

CCOc1cc(C(=O)OC)cc(OCC)c1-c1cnn(C2CC2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKAB2 O43741 1/20 0.40
ABL1 P00519 1/20 0.40
CSF1R P07333 1/20 0.40
LYN P07948 1/20 0.40
TGFBR1 P36897 1/20 0.40
PRKAG1 P54619 1/20 0.40
SIK1 P57059 1/20 0.40
PRKAA1 Q13131 1/20 0.40
SIK2 Q9H0K1 1/20 0.40
SIK3 Q9Y2K2 1/20 0.40
S1PR1 P21453 1/20 0.38
AXL P30530 2/20 0.37
TYRO3 Q06418 2/20 0.37
MERTK Q12866 2/20 0.37
PAK1 Q13153 1/20 0.37
GSK3B P49841 5/20 0.37
DYRK1A Q13627 5/20 0.37
WNT1 P04628 2/20 0.37
LOXL2 Q9Y4K0 2/20 0.37
NLRP3 Q96P20 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL731831 0.88 TSHR (0.39) PRKAB2ABL1CSF1RLYNTGFBR1
SCHEMBL731379 0.84 PDK2 (0.45) PRKAB2ABL1CSF1RLYNTGFBR1
SCHEMBL730899 0.81 AAK1 (0.44) PRKAB2ABL1CSF1RLYNTGFBR1
SCHEMBL732896 0.77 RIPK1 (0.38)
SCHEMBL23535778 0.75 ALDH1A1 (0.46) GSK3BDYRK1AWNT1CREBBPACHE
SCHEMBL17162236 0.74 ACHE (0.51) GSK3BDYRK1AACHE
SCHEMBL731854 0.72 AAK1 (0.49) ABL1AXLTYRO3MERTKCREBBP
SCHEMBL23365591 0.72 MAP3K5 (0.53) PRKAB2ABL1CSF1RLYNTGFBR1
SCHEMBL731308 0.72 MAP4K4 (0.45) LOXL2SSTR5
SCHEMBL733580 0.72 ROCK2 (0.46) S1PR1CREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 PRKAB2 4130/4885ABL1 1084/4885CSF1R 3219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.